Home>>Signaling Pathways>> Neuroscience>> Behavioral Neuroscience>>Flumazenil-d5

Flumazenil-d5

Catalog No.GC90346

An internal standard for the quantification of flumazenil

Products are for research use only. Not for human use. We do not sell to patients.

Flumazenil-d5 Chemical Structure

Cas No.: 2700278-14-2

Size Price Stock Qty
2.5 mg
$473.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Flumazenil-d5 is intended for use as an internal standard for the quantification of flumazenil by GC- or LC-MS. Flumazenil is a GABAA receptor antagonist (IC50 = 2 nM in a radioligand binding assay using rat cortical synaptosomes).1 Flumazenil also acts as a partial agonist of GABAA receptors, decreasing the amplitude of electrically stimulated population spikes in rat hippocampal CA1 pyramidal neurons.2 It increases the number of entries into the open arms of the elevated plus maze in high-anxiety BALB/c, but not C57BL/6, mice when administered at doses ranging from 0.1 to 1,000 µg/kg.3 Flumazenil (5 and 10 mg/kg) prevents a reduction in burying behavior induced by the GABAA receptor positive allosteric modulator allopregnanolone in ovariectomized rats when administered at doses of 5 and 10 mg/kg.4 Formulations containing flumazenil have been used to reverse sedation induced by benzodiazepines and in the treatment of benzodiazepine overdose or withdrawal.

Reviews

Review for Flumazenil-d5

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Flumazenil-d5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.